Dymista is a combination of azelastine HCL and fluticasone propionate nasal spray formulation for the treatment of seasonal allergic rhinitis in patients 12 years and older.
49% of patients treated with Dymista achieved 50% improvement in rTNSS (Total Nasal Symptom Score).
Patients treated with Dymista reached response 5–6 days earlier than patients treated with fluticasone or azelastine monotherapy. Onset of action was achieved within 30 minutes.
It also reduced ocular rTOSS (Total Ocular Symptom Score) symptoms to a greater extent than fluticasone.
Dymista (azelastine and fluticasone) will be available in August 2012. Here is the official website: http://www.dymista.com/hcp
Treatment Options for Allergic Rhinitis (AR) and Non-Allergic Rhinitis (NAR) (click to enlarge the image).
Phase 3 Results for Dymista for Allergic Rhinitis
Comments from Twitter:
Reinaldo B. @basanezrx: (Dymista's cost is) probably around $150-200 for one month only.